Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 923 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05469893RecruitingPhase 2
Targeted treatment for high-risk smoldering myeloma
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
Denver, ColoradoAges 18 years+ - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05597345RecruitingPhase 2
Selinexor for higher-risk smoldering myeloma
This trial studies selinexor, a medicine taken by mouth, to slow or treat intermediate- or high-risk smoldering multiple myeloma before it becomes symptomatic. It may help some people reduce disease progression, based on how well the treatment controls the abnormal plasma cells.
Rochester, New YorkAges 18 years+ - NCT05601726RecruitingPhase 1/Phase 2
Study of a new drug for hard-to-treat AML or high-risk MDS
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
Marseille, FranceAges 18 years+ - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05650749RecruitingPhase 1
CAR T-cell treatment for hard-to-treat neuroblastoma or retinoblastoma
This Phase 1 study tests a lab-made immune cell therapy (CAR T cells) made to find GPC2, for children and young adults with relapsed or refractory neuroblastoma or metastatic retinoblastoma. The goal is to see whether the cells can shrink tumors and be tolerated in people whose standard treatments did not work.
Philadelphia, PennsylvaniaAges 1 year+ - NCT05662462Recruiting
Phone coaching to keep blood sugar in range during pregnancy
This study tests whether technology plus coaching can help pregnant people with type 2 diabetes keep their blood sugar in a healthy target range. You may use a smartphone app and, if assigned to that group, a device that tracks glucose continuously.
Columbus, OhioAges 18 years+ - NCT05662696Recruiting
Telemonitoring for pregnant people at high risk of preeclampsia
This study tests whether a home telemonitoring program (sending health readings from home) is practical and helpful for people at high risk for preeclampsia. It may help catch warning signs earlier and support safer care during the first half of pregnancy.
Karachi, SindhAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05686434RecruitingPhase 2
Osimertinib after surgery for early-stage EGFR-mutated lung cancer
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05707819Recruiting
Sintilimab plus chemoradiotherapy for high-risk nasopharyngeal cancer
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Nanning, GuangxiAges 18–70 - NCT05722405RecruitingPhase 4
Ixazomib plus lenalidomide compared to ixazomib alone for myeloma maintenance
This trial studies whether adding low-dose lenalidomide to ixazomib can help keep high-risk multiple myeloma from coming back after initial treatment. It may help prolong the time before the disease worsens, while also checking side effects.
Hangzhou, ZhejiangAges 18–80 - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05726526Recruiting
Phone app monitoring to help people with advanced kidney disease
This study tests a phone app (with check-ins on things like blood pressure and weight) to help prevent complications in people with advanced chronic kidney disease. You may be a good match if you’re high risk and can actively measure and share your health data with a kidney care team.
Winnipeg, ManitobaAges 18 years+ - NCT05732974Recruiting
Using a computer tool to find lung cancer relapse risk
This study uses a machine-learning computer method to identify people with early-stage lung cancer who have a higher risk of the cancer coming back after surgery. If you qualify, your information may help researchers improve how doctors predict relapse and plan follow-up care.
ToulouseAges 18 years+ - NCT05739123Recruiting
Pregnancy safety registry for relugolix-containing medicines
This is an observational study that collects real-world information about pregnancy outcomes when relugolix-containing therapy is taken during pregnancy. It aims to better understand safety for both the parent during pregnancy and the child after birth.
Wilmington, North CarolinaAges birth+ - NCT05746793Recruiting
IVF pregnancy study to prevent pre-eclampsia in high-risk women
This trial studies ways to lower the risk of pre-eclampsia (dangerous high blood pressure in pregnancy) in women who are having a first pregnancy through IVF/ICSI or who have PCOS. It’s aimed at people considered higher risk for pre-eclampsia.
BrusselsAges 18–48 - NCT05765175Recruiting
Radioablation versus repeat ablation for hard-to-treat VT
This trial compares a heart procedure using targeted radiation (called radioablation) to a repeat catheter ablation for people with high-risk, hard-to-control ventricular tachycardia (VT). It aims to find which approach is safer and works better after standard ablation and amiodarone have not stopped the abnormal rhythm.
Los Angeles, CaliforniaAges 18 years+ - NCT05776979RecruitingPhase 2
Isatuximab plus lenalidomide after transplant for high-risk myeloma
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Houston, TexasAges 18–72 - NCT05781438Recruiting
In-home standing and walking help for infants at CP risk
This study tests a program that helps infants stand and walk at home. It may help babies with cerebral palsy—or those at high risk—by improving movement and function in a safe, supported way.
Los Angeles, CaliforniaAges 5 months–2 years - NCT05786235Recruiting
Pregnant people with or without antiphospholipid antibodies
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
MilanAges 18–45 - NCT05786495Recruiting
Short antibiotic treatment for high-risk fever with low white cells
This study tests whether adults with “high-risk febrile neutropenia” can safely get a shorter course of antibiotics. It may help reduce side effects from antibiotics while still keeping infections under control.
EdmontonAges 18 years+
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 923 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.